

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

Rb (D20) Rabbit mAb

RRID:AB_1904119

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9313, RRID:AB_1904119

Antibody Information

URL: http://antibodyregistry.org/AB_1904119

Proper Citation: Cell Signaling Technology Cat# 9313, RRID:AB_1904119

Target Antigen: Rb (D20) Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, ChIP

Antibody Name: Rb (D20) Rabbit mAb

Description: This monoclonal targets Rb (D20) Rabbit mAb

Target Organism: h, m, mouse, human, mk

Antibody ID: AB_1904119

Vendor: Cell Signaling Technology

Catalog Number: 9313

Record Creation Time: 20231110T072631+0000

Record Last Update: 20260831T220613+0000

Ratings and Alerts

- ENCODE PROJECT External validation for lot: 2 is available under ENCODE ID: ENCAB000BFB - ENCODE
<https://www.encodeproject.org/antibodies/ENCAB000BFB>

No alerts have been found for Rb (D20) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Berardi V, et al. (2026) Regulatory BC200 RNA promotes breast carcinogenesis by repressing BRCA1 gene expression. *iScience*, 29(4), 115267.

Lamichhane A, et al. (2025) Targeting CAFs-Mediated Stromal Signaling in a Patient-Derived Organotypic Colorectal Tumor Model. *Molecular cancer therapeutics*, 24(8), 1265.

Gao Y, et al. (2025) Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. *Cell reports. Medicine*, 6(11), 102434.

Zhang D, et al. (2025) FLT3L-based drug conjugate effectively targets chemoresistant leukemia stem cells in acute myeloid leukemia. *Cell reports. Medicine*, 102365.

Hu X, et al. (2025) The transcription factor MEF2C restrains microglial overactivation by inhibiting kinase CDK2. *Immunity*, 58(4), 946.

Papismadov N, et al. (2024) p21 regulates expression of ECM components and promotes pulmonary fibrosis via CDK4 and Rb. *The EMBO journal*, 43(22), 5360.

Chen A, et al. (2024) PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. *Molecular cancer therapeutics*, 23(10), 1494.

Rona G, et al. (2024) CDK-independent role of D-type cyclins in regulating DNA mismatch repair. *Molecular cell*.

Wang S, et al. (2024) Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer. *Cancer research*.

Zhou Z, et al. (2024) Type 2 cytokine signaling in macrophages protects from cellular senescence and organismal aging. *Immunity*, 57(3), 513.

Nasser AM, et al. (2024) CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(14), 2996.

Loi P, et al. (2024) Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers. *Cancer discovery*, 14(12), 2430.

He Y, et al. (2023) Numb/Parkin-directed mitochondrial fitness governs cancer cell fate via metabolic regulation of histone lactylation. *Cell reports*, 42(2), 112033.

Müller L, et al. (2023) Plakophilin 3 facilitates G1/S phase transition and enhances proliferation by capturing RB protein in the cytoplasm and promoting EGFR signaling. *Cell reports*, 42(1), 112031.

Flint AC, et al. (2023) Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(17), 3438.

Xiang S, et al. (2023) Identification of Selective ATP-Competitive CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function. *Research square*.

Du H, et al. (2023) Suppression of TREX1 deficiency-induced cellular senescence and interferonopathies by inhibition of DNA damage response. *iScience*, 26(7), 107090.

Freeman-Cook K, et al. (2021) Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. *Cancer cell*, 39(10), 1404.

Zhu Q, et al. (2021) Rack1 is essential for corticogenesis by preventing p21-dependent senescence in neural stem cells. *Cell reports*, 36(9), 109639.

Wenthe J, et al. (2021) Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. *Cancer immunology, immunotherapy : CII*, 70(10), 2851.